These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 28986618)

  • 1. [
    Boegemann M; Schrader AJ; Rahbar K
    Urologe A; 2017 Nov; 56(11):1440-1444. PubMed ID: 28986618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PSMA radioligand therapy in patients with advanced prostate cancer].
    Bögemann M; Herrmann K; Radtke JP; Rahbar K
    Urologe A; 2020 Jun; 59(6):680-686. PubMed ID: 32333064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Satapathy S; Sahoo RK; Bal C
    J Nucl Med; 2023 Aug; 64(8):1266-1271. PubMed ID: 37169534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of short-term dexamethasone on the efficacy of
    Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
    Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes of
    Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
    J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and Efficacy of [
    Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
    J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
    [No Abstract]   [Full Text] [Related]  

  • 8. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
    Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on radioligand therapy with
    Fuoco V; Argiroffi G; Mazzaglia S; Lorenzoni A; Guadalupi V; Franza A; Scalorbi F; Aliberti G; Chiesa C; Procopio G; Seregni E; Maccauro M
    Tumori; 2022 Aug; 108(4):315-325. PubMed ID: 34405748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Single-Arm, Low-Dose, Prospective Study of
    Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
    J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer : Oncological Outcomes and Toxicity Profile.
    Demirkol MO; Esen B; Seymen H; Şen M; Uçar B; Kurtuldu S; Mandel NM; Bavbek S; Falay O; Tilki D; Esen T
    Clin Nucl Med; 2023 Dec; 48(12):e564-e569. PubMed ID: 37844332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed response after repeated
    Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.
    Rahbar K; Bode A; Weckesser M; Avramovic N; Claesener M; Stegger L; Bögemann M
    Clin Nucl Med; 2016 Jul; 41(7):522-8. PubMed ID: 27088387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and safety of rechallenge [
    Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
    Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
    Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
    Almuradova E; Seyyar M; Arak H; Tamer F; Kefeli U; Koca S; Sen E; Telli TA; Karatas F; Gokmen I; Turhal NS; Sakalar T; Ayhan M; Ekinci F; Hafizoglu E; Kahraman S; Kesen O; Unal C; Alan O; Celik S; Yekeduz E; Omur O; Gokmen E
    Int J Cancer; 2024 Feb; 154(4):692-700. PubMed ID: 37818966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoption of Lutetium-
    Flegar L; Thoduka SG; Librizzi D; Luster M; Zacharis A; Heers H; Eisenmenger N; Ahmadzadehfar H; Eiber M; Weber W; Groeben C; Huber J
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2188-2195. PubMed ID: 36826478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.